Today’s pharmacovigilance (PV) teams face mounting pressure to analyze increasingly larger volumes of safety data while meeting progressively complex global reporting expectations. According to Deloitte’s 2026 Life Sciences Outlook, 48% of life sciences executives say the rapid adoption of digital technologies and data analytics will substantially impact their organizations. Another area of growing interest is…